Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
EMD Serono
AstraZeneca
Sanofi
Abramson Cancer Center at Penn Medicine
Wake Forest University Health Sciences
NRG Oncology
Checkpoint Therapeutics, Inc.
Novartis
Novartis
Samsung Bioepis Co., Ltd.
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
Spanish Lung Cancer Group
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
On Target Laboratories, LLC
Innovent Biologics (Suzhou) Co. Ltd.
Bristol-Myers Squibb
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Stanford University
AstraZeneca
Milton S. Hershey Medical Center
Takeda
RTOG Foundation, Inc.
Genentech, Inc.
Merck Sharp & Dohme LLC
Celgene
Eli Lilly and Company
Incyte Corporation
SWOG Cancer Research Network
Radiation Therapy Oncology Group
Daiichi Sankyo
Alliance for Clinical Trials in Oncology
Beth Israel Deaconess Medical Center
Alliance for Clinical Trials in Oncology
Sanofi
Par Pharmaceutical, Inc.
Martha-Maria Krankenhaus Halle-Dölau gGmbH
Astellas Pharma Inc
Virginia Commonwealth University
Sumitomo Pharma (Suzhou) Co., Ltd.